These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 19593954)

  • 1. The influence of rosuvastatin therapy and percutaneous coronary intervention on angiogenic growth factors in coronary artery disease patients.
    Semenova AE; Sergienko IV; Masenko VP; Ezhov MV; Gabrusenko SA; Kuharchuk VV; Belenkov YN
    Acta Cardiol; 2009 Jun; 64(3):405-9. PubMed ID: 19593954
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effect of rosuvastatin therapy and myocardial revascularization on angiogenesis in coronary artery disease patients].
    Semenova AE; Sergienko IV; Masenko VP; Gabrusenko SA; Kukharchuk VV; Belenkov IuN
    Kardiologiia; 2007; 47(11):4-8. PubMed ID: 18260956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effect of statin therapy on dynamics of vascular endothelial growth factor and fibroblast growth factor in patients with ischemic heart disease].
    Sergienko IV; Semenova AE; Masenko VP; Ezhov MV; Gabrusenko SA; Kukharchuk VV; Belenkov IuN
    Kardiologiia; 2007; 47(8):4-7. PubMed ID: 18260902
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effect of therapy with rosuvastatin on lipid spectrum, factors of inflammation and endothelial function in patients with ischemic heart disease].
    Sergienko IV; Samoĭlenko EIu; Masenko VP; Ezhov MV; Sumarokov AB; Tkachev GA; Pogorelova OA; Balakhonova TV; Naumov VG
    Kardiologiia; 2006; 46(5):4-8. PubMed ID: 16858347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Rosuvastatin improves myocardial function and arteriosclerosis plaque in patients with ST-segment elevation after acute myocardial infarction and percutaneous coronary intervention].
    Lin ZP; Shu PC; Liao ZJ; Wang XQ; Liu Q
    Nan Fang Yi Ke Da Xue Xue Bao; 2011 Oct; 31(10):1789-91. PubMed ID: 22027793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of intensive lipid lowering on lipid profiles over time and tolerability in stable coronary artery disease: insights from a subanalysis of the coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japanese subjects (COSMOS).
    Kawashiri MA; Yamagishi M; Sakamoto T; Takayama T; Hiro T; Daida H; Hirayama A; Saito S; Yamaguchi T; Matsuzaki M;
    Cardiovasc Ther; 2013 Dec; 31(6):335-43. PubMed ID: 23409830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of high-dose rosuvastatin loading before percutaneous coronary intervention in female patients with non-ST-segment elevation acute coronary syndrome.
    Gao Y; Jia ZM; Sun YJ; Zhang ZH; Ren LN; Qi GX
    Chin Med J (Engl); 2012 Jul; 125(13):2250-4. PubMed ID: 22882843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. C-reactive protein, but not low-density lipoprotein cholesterol levels, associate with coronary atheroma regression and cardiovascular events after maximally intensive statin therapy.
    Puri R; Nissen SE; Libby P; Shao M; Ballantyne CM; Barter PJ; Chapman MJ; Erbel R; Raichlen JS; Uno K; Kataoka Y; Nicholls SJ
    Circulation; 2013 Nov; 128(22):2395-403. PubMed ID: 24043299
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term effects of maximally intensive statin therapy on changes in coronary atheroma composition: insights from SATURN.
    Puri R; Libby P; Nissen SE; Wolski K; Ballantyne CM; Barter PJ; Chapman MJ; Erbel R; Raichlen JS; Uno K; Kataoka Y; Tuzcu EM; Nicholls SJ
    Eur Heart J Cardiovasc Imaging; 2014 Apr; 15(4):380-8. PubMed ID: 24448227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of a single high loading dose of rosuvastatin on percutaneous coronary intervention for acute coronary syndromes.
    Wang Z; Dai H; Xing M; Yu Z; Lin X; Wang S; Zhang J; Hou F; Ma Y; Ren Y; Tan K; Wang Y; Ge Z
    J Cardiovasc Pharmacol Ther; 2013 Jul; 18(4):327-33. PubMed ID: 23364255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Rosuvastatin and fenofibrate in patients with diabetes and low high density lipoprotein cholesterol: comparison of changes of lipid levels and some markers of inflammation].
    Polenova NV; Vaulin NA; Masenko VP; Iavelov IS; Gratsianskiĭ NA
    Kardiologiia; 2009; 49(2):9-14. PubMed ID: 19254210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER).
    Ridker PM; MacFadyen JG; Fonseca FA; Genest J; Gotto AM; Kastelein JJ; Koenig W; Libby P; Lorenzatti AJ; Nordestgaard BG; Shepherd J; Willerson JT; Glynn RJ;
    Circ Cardiovasc Qual Outcomes; 2009 Nov; 2(6):616-23. PubMed ID: 20031900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NLRP3 inflammasome activation in coronary artery disease: results from prospective and randomized study of treatment with atorvastatin or rosuvastatin.
    Satoh M; Tabuchi T; Itoh T; Nakamura M
    Clin Sci (Lond); 2014 Feb; 126(3):233-41. PubMed ID: 23944632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of two intensive statin regimens on progression of coronary disease.
    Nicholls SJ; Ballantyne CM; Barter PJ; Chapman MJ; Erbel RM; Libby P; Raichlen JS; Uno K; Borgman M; Wolski K; Nissen SE
    N Engl J Med; 2011 Dec; 365(22):2078-87. PubMed ID: 22085316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [JUPITER: reduction by rosuvastatin of cardiovascular events and mortality in healthy subjects without hyperlipidaemia but with elevated C-reactive protein].
    Scheen AJ
    Rev Med Liege; 2008 Dec; 63(12):749-53. PubMed ID: 19180837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial.
    Nissen SE; Nicholls SJ; Sipahi I; Libby P; Raichlen JS; Ballantyne CM; Davignon J; Erbel R; Fruchart JC; Tardif JC; Schoenhagen P; Crowe T; Cain V; Wolski K; Goormastic M; Tuzcu EM;
    JAMA; 2006 Apr; 295(13):1556-65. PubMed ID: 16533939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rosuvastatin-induced high-density lipoprotein changes in patients who underwent percutaneous coronary intervention for non-ST-segment elevation acute coronary syndrome.
    Yun KH; Shin SN; Ko JS; Rhee SJ; Kim NH; Oh SK; Jeong JW
    J Cardiol; 2012 Nov; 60(5):383-8. PubMed ID: 22884684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
    Strandberg TE; Feely J; Sigurdsson EL;
    Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of effects of atorvastatin (20 mg) versus rosuvastatin (10 mg) therapy on mild coronary atherosclerotic plaques (from the ARTMAP trial).
    Lee CW; Kang SJ; Ahn JM; Song HG; Lee JY; Kim WJ; Park DW; Lee SW; Kim YH; Park SW; Park SJ
    Am J Cardiol; 2012 Jun; 109(12):1700-4. PubMed ID: 22440123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors underlying regression of coronary atheroma with potent statin therapy.
    Puri R; Nissen SE; Ballantyne CM; Barter PJ; Chapman MJ; Erbel R; Libby P; Raichlen JS; St John J; Wolski K; Uno K; Kataoka Y; Nicholls SJ
    Eur Heart J; 2013 Jun; 34(24):1818-25. PubMed ID: 23644179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.